These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 24195247)
1. [Refractory anemias]. Efira A; Azerad MA Rev Med Brux; 2013 Sep; 34(4):323-7. PubMed ID: 24195247 [TBL] [Abstract][Full Text] [Related]
2. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies]. Aul C; Giagounidis A; Germing U; Ganser A Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275 [TBL] [Abstract][Full Text] [Related]
3. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. Cermák J; Vítek A; Michalová K Leuk Res; 2004 Jun; 28(6):551-7. PubMed ID: 15120930 [TBL] [Abstract][Full Text] [Related]
4. Refractory anemia and the myelodysplastic syndromes. Lawrence LW Clin Lab Sci; 2004; 17(3):178-86. PubMed ID: 15314893 [TBL] [Abstract][Full Text] [Related]
5. [Myelodysplastic syndrome]. Urabe A Gan To Kagaku Ryoho; 2005 Mar; 32(3):287-91. PubMed ID: 15791810 [TBL] [Abstract][Full Text] [Related]
6. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Runde V; de Witte T; Arnold R; Gratwohl A; Hermans J; van Biezen A; Niederwieser D; Labopin M; Walter-Noel MP; Bacigalupo A; Jacobsen N; Ljungman P; Carreras E; Kolb HJ; Aul C; Apperley J Bone Marrow Transplant; 1998 Feb; 21(3):255-61. PubMed ID: 9489648 [TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System. Mirza I; Garzón R; Burns J; Edwards L; Fernandez-Cymering C; Kloss R Conn Med; 2001 Aug; 65(8):455-63. PubMed ID: 11550445 [TBL] [Abstract][Full Text] [Related]
8. [Myelodysplastic syndromes or refractory anemias]. Fenaux P Rev Prat; 1993 Jun; 43(11):1379-85. PubMed ID: 8235387 [TBL] [Abstract][Full Text] [Related]
9. Detection of risk groups in myelodysplastic syndromes. A multicenter study. Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460 [TBL] [Abstract][Full Text] [Related]
10. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Beran M Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661 [TBL] [Abstract][Full Text] [Related]
11. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis. Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299 [TBL] [Abstract][Full Text] [Related]
12. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Kao JM; McMillan A; Greenberg PL Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988 [TBL] [Abstract][Full Text] [Related]
13. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935 [TBL] [Abstract][Full Text] [Related]